CTOs on the Move

Immunomic Therapuetics

www.immunomix.com

 
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.immunomix.com
  • 1214 Research Blvd Suite 2016
    Hershey, PA USA 17036
  • Phone: 717.327.1919

Executives

Name Title Contact Details

Funding

Immunomic Therapuetics raised $61.3M on 04/23/2020

Similar Companies

CepTor Corporation

CepTor Corporation is a Cockeysville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

British Columbia Cancer Agcy

British Columbia Cancer Agcy is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Laboratory for Advanced Medicine

The Laboratory for Advanced Medicine, Inc. (LAM) is a bio-pharmaceutical company dedicated to developing revolutionary non-invasive, non-toxic technologies for disease diagnosis and intervention, with an emphasis on cancer.

Pharmathene

Pharmathene, Inc is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.